TROG 15.02 (ROAM)

Primary sponsor: The Walton Centre NHS Foundation Trust, University of Liverpool, UK
Collaborating group: European Organisation for Research and Treatment of Cancer (EORTC) ; Trans Tasman Radiation Oncology Group (TROG)

Title

Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Summary

Atypical meningioma is a tumour that arises from the lining of the brain. It mostly affects adults, with most patients in the 40-60 year age group. The primary treatment for atypical meningioma is surgical removal, but with surgery alone up to 40% of patients will experience recurrence. Because of this risk, some clinicians give early radiotherapy, whilst others advise regular monitoring with radiotherapy given only at recurrence. Currently there is no consensus as to which of these two approaches is best. This randomised controlled trial will compare the two approaches, and aims to determine whether early radiotherapy reduces the risk of tumour recurrence compared to regular monitoring in newly diagnosed atypical meningioma.

Participating centres

Current participating centres (PDF)

Accrual Target

Current Accrual Graph

Current accrual graph (PDF)

Expected Date of Accrual Completion

September 2021

Trial chairperson

Dr Gail Ryan, Peter MacCallum Cancer Centre, VIC

Trial contact

TROG Trial Coordinating Centre
Phone: +61 2 4014 3911
Email: ROAM@trog.com.au

Trial resources for TROG members

TROG 15.02 member page

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.

Tweets by @TROGfightcancer